Morgan Stanley’s Therapix Biosciences Ltd. TRPX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-436,189
| Closed | -$271K | – | 6983 |
|
|
2020
Q2 | $271K | Buy |
436,189
+424,656
| +3,682% | +$205K | ﹤0.01% | 4931 |
|
|
2020
Q1 | $5K | Buy |
11,533
+10,030
| +667% | +$5.69K | ﹤0.01% | 6248 |
|
|
2019
Q4 | $2K | Sell |
1,503
-837
| -36% | -$1.54K | ﹤0.01% | 6535 |
|
|
2019
Q3 | $6K | Sell |
2,340
-7,865
| -77% | -$19.9K | ﹤0.01% | 6350 |
|
|
2019
Q2 | $26K | Sell |
10,205
-24,711
| -71% | -$76.6K | ﹤0.01% | 5848 |
|
|
2019
Q1 | $109K | Sell |
34,916
-14,422
| -29% | -$58.6K | ﹤0.01% | 5351 |
|
|
2018
Q4 | $160K | Buy |
49,338
+41,448
| +525% | +$240K | ﹤0.01% | 5372 |
|
|
2018
Q3 | $34K | Sell |
7,890
-1,697
| -18% | -$6.58K | ﹤0.01% | 5994 |
|
|
2018
Q2 | $39K | Buy |
9,587
+470
| +5% | +$2.13K | ﹤0.01% | 5981 |
|
|
2018
Q1 | $52K | Sell |
9,117
-1,000
| -10% | -$5.77K | ﹤0.01% | 5876 |
|
|
2017
Q4 | $54K | Sell |
10,117
-133
| -1% | -$711 | ﹤0.01% | 5815 |
|
|
2017
Q3 | $59K | Sell |
10,250
-1,000
| -9% | -$5.99K | ﹤0.01% | 5738 |
|
|
2017
Q2 | $79K | Sell |
11,250
-13,212
| -54% | -$91.9K | ﹤0.01% | 5723 |
|
|
2017
Q1 | $198K | Buy |
+24,462
| New | +$215K | ﹤0.01% | 5330 |
|
Morgan Stanley's TRPX Position: Q3 2020 in Review
Morgan Stanley sold out of Therapix Biosciences Ltd. (TRPX) in Q3 2020, closing a stake of 436,189 shares — an estimated $271K sold.
Morgan Stanley first reported a position in TRPX in Q1 2017 and held it in 14 quarters. The position peaked at $271K in Q2 2020. 0 funds tracked by Wall St. Rank hold TRPX as of Q3 2020.
- Morgan Stanley reported no remaining Therapix Biosciences Ltd. position as of Q3 2020 after selling out during the quarter.
- Morgan Stanley sold 436,189 Therapix Biosciences Ltd. shares in Q3 2020, an estimated $271K.
- Morgan Stanley first reported a position in Therapix Biosciences Ltd. in Q1 2017 and held it in 14 quarters.
- Morgan Stanley's Therapix Biosciences Ltd. position peaked at $271K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q3 2020.
Based on Morgan Stanley's 13F filing for Q3 2020, filed 13 Nov 2020.